Neoadjuvant Therapy Clinical Trial
Official title:
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma:A Single Arm, Single Center, Prospective Clinical Trial (POINTS Trial)
The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (cadonilimab) in combination with platinum-containing chemotherapy (paclitaxel polymer micelles combined with cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with cadonilimab combined with chemotherapy.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | June 20, 2025 |
Est. primary completion date | April 20, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age =18 years, =75 years, gender is not limited; 2. Squamous esophageal cancer of thoracic segment confirmed by pathology; 3. Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable after discussion among oncology, esophageal surgery, and imaging, and clinical stage cT2-4aN+ or cT3-4aN0, M0, stage II, III, or IVA (AJCC 8th edition cTNM staging); 4. ECOG PS score of 0-1; 5. No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy; 6. Expected survival > 6 months; 7. Adequate baseline organ function: (i) WBC =3×10^9/L, ANC =1.5×10^9/L, PLT =100×10^9/L, Hb =9g/dL; (ii) Liver function: TBIL =2ULN, AST =2.5ULN, ALT =2.5ULN; (iii) Renal function: cCr>40 ml/min, Cr=1.5 ULN; (iv) Cardiac function: no cardiac disease or coronary artery disease. Cardiac function: no heart disease or coronary heart disease, patients with cardiac function grade 1-2; 8. Hypertensive patients applying antihypertensive drugs to control blood pressure within the normal range; 9. Diabetic patients with fasting blood glucose controlled at =8mmol/L by hypoglycemic drug treatment; 10. No other serious diseases (such as autoimmune diseases, immunodeficiency, organ transplantation, or other diseases that require continuous hormone therapy) that conflict with this protocol; 11. No history of other malignant tumors; 12. The patient agrees to participate in this clinical study and signs the Informed Consent Form. Exclusion Criteria: 1. Patients who have previously received anti-tumor therapy (including chemotherapy, radiotherapy, surgery or immunotherapy, etc.); 2. Combination of other incurable malignant tumors (except cured non-malignant skin tumors, cervical cancer in situ, and prostate cancer); 3. Patient has or anticipates a significant risk of esophageal perforation, fistula, and hemorrhage; 4. Active autoimmune or immunodeficiency disease, use of immunosuppressants prior to enrollment, and use of immunosuppressant dosage =10 mg/day of oral prednisone for more than 2 weeks; 5. Clinically significant cardiovascular disease including, but not limited to, severe acute myocardial infarction, unstable or severe angina pectoris, coronary artery bypass grafting surgery, congestive heart failure, ventricular arrhythmia requiring medical intervention, left ventricular ejection fraction <50%, or other anticipated inability to tolerate chemoradiotherapy in the 6 months prior to enrollment; 6. Severe allergies; 7. Pregnant or lactating women; 8. Severe mental disorders; 9. Presence of CTC grade =3 peripheral nerve disease; 10. Abnormal coagulation function (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), bleeding tendency or undergoing thrombolytic or anticoagulant therapy; 11. Presence of severe pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, severe impairment of lung function, or active tuberculosis within 1 year; 12. Presence of active hepatitis B or C; 13. Any other condition that the investigator evaluates to be ineligible for enrollment. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sun Jing |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathological complete response (pCR) rates | evaluate pathological complete response rate of primary tumor and locally metastatic lymph nodes after 2-4 cycles of neoadjuvant therapy. | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks. | |
Secondary | Objective Rate of Effectiveness (ORR) | the proportion of patients who achieve PR or CR | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks. | |
Secondary | R0 Removal Rate | Rate of microscopically margin-negative resection | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks. | |
Secondary | 2-year overall survival rate | 2-year overall survival rate | 2 years | |
Secondary | 2-year disease free survival rate | 2-year disease free survival rate | 2 years | |
Secondary | major pathological response (MPR) | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04520737 -
Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases
|
N/A | |
Recruiting |
NCT06138496 -
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
|
Phase 2 | |
Not yet recruiting |
NCT05983094 -
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
|
Phase 2 | |
Terminated |
NCT04440982 -
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04028375 -
Study of CT and MR in the Gastric Cancer
|
||
Active, not recruiting |
NCT03192735 -
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04588987 -
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
|
Phase 2 | |
Not yet recruiting |
NCT05993858 -
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
|
Phase 2 | |
Active, not recruiting |
NCT04666090 -
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04848454 -
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
|
Phase 2 | |
Recruiting |
NCT04062058 -
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT06124378 -
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06125223 -
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
|
||
Not yet recruiting |
NCT06404736 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404463 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05371197 -
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06212440 -
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
|
N/A | |
Completed |
NCT03178032 -
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
|
Phase 1 |